Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 1467 entries
View as:

Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA

Phase: N/A Priority: Normal
NCT ID: NCT05245071 Org: User:
Start: 06/01/22 End: 11/20/24 Due: 11/20/25

Lantus Effect on Myocardial Glucose Metabolism in T2

Phase: N/A Priority: Normal
NCT ID: NCT00335465 Org: User:
Start: 09/30/05 End: 06/30/08 Due: 06/30/09

A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)

Phase: N/A Priority: Normal
NCT ID: NCT05526521 Org: User:
Start: 08/25/22 End: 02/03/25 Due: 02/03/26

A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

Phase: N/A Priority: Normal
NCT ID: NCT05206773 Org: User:
Start: 03/11/22 End: 12/02/26 Due: 12/02/27

Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)

Phase: N/A Priority: Normal
NCT ID: NCT02134028 Org: User:
Start: 08/05/14 End: 10/11/19 Due: 10/11/20

Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT00981240 Org: User:
Start: 09/30/09 End: 02/29/12 Due: 02/28/13

Study of the Tolerability of Different SAR153191 Drug Products, That Differ With Respect to Manufacturing Processes and Formulation, at Different Concentrations and Doses in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06159452 Org: User:
Start: 07/09/10 End: 12/21/10 Due: 12/21/11

Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00081796 Org: User:
Start: 04/30/04 End: 09/30/06 Due: 09/30/07

A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01596270 Org: User:
Start: 06/30/12 End: 10/31/14 Due: 10/31/15

Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation

Phase: N/A Priority: Normal
NCT ID: NCT00396877 Org: User:
Start: 11/30/06 End: 02/28/10 Due: 02/28/11

MASCOT : Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV

Phase: N/A Priority: Normal
NCT ID: NCT00263055 Org: User:
Start: 08/31/04 End: - Due: -

Safety of Single Doses of SAR113945 and Efficacy and Safety of a New Formulation Given Into the Knee in Osteoarthritis Patients / Part II

Phase: N/A Priority: Normal
NCT ID: NCT01598415 Org: User:
Start: 04/30/12 End: 02/28/13 Due: 02/28/14

An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder

Phase: N/A Priority: Normal
NCT ID: NCT00417118 Org: User:
Start: 12/31/06 End: 04/30/08 Due: 04/30/09

Levofloxacin, Chronic Bacterial Prostatitis

Phase: N/A Priority: Normal
NCT ID: NCT00277511 Org: User:
Start: 03/31/03 End: - Due: -

Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00549185 Org: User:
Start: 10/31/07 End: 01/31/12 Due: 01/31/13

Avalglucosidase Alfa Pregnancy Study

Phase: N/A Priority: Normal
NCT ID: NCT05734521 Org: User:
Start: 10/26/22 End: 10/31/32 Due: 10/31/33

A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03871348 Org: User:
Start: 01/03/19 End: 02/21/24 Due: 02/21/25

A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

Phase: N/A Priority: Normal
NCT ID: NCT06145373 Org: User:
Start: 03/01/24 End: 05/19/28 Due: 05/19/29

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria

Phase: N/A Priority: Normal
NCT ID: NCT02497612 Org: User:
Start: 07/25/15 End: 09/23/19 Due: 09/23/20

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

Phase: N/A Priority: Normal
NCT ID: NCT02787551 Org: User:
Start: 07/06/16 End: 11/17/18 Due: 11/17/19

Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT00475865 Org: User:
Start: 04/30/07 End: 10/31/09 Due: 10/31/10

Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma

Phase: N/A Priority: Normal
NCT ID: NCT00044824 Org: User:
Start: 02/28/02 End: 10/31/03 Due: 10/31/04

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin

Phase: N/A Priority: Normal
NCT ID: NCT00715624 Org: User:
Start: 07/31/08 End: 02/28/11 Due: 02/28/12

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

Phase: N/A Priority: Normal
NCT ID: NCT06676319 Org: User:
Start: 11/07/24 End: 11/12/27 Due: 11/12/28

Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]

Phase: N/A Priority: Normal
NCT ID: NCT00268710 Org: User:
Start: 02/29/04 End: 03/31/06 Due: 03/31/07